跳至主要内容
临床试验/EUCTR2008-002299-92-IT
EUCTR2008-002299-92-IT进行中(未招募)不适用

METRONOMIC CAPECITABINE IN ADVANCED HEPATOCARCINOMA:A FASE II STUDY - Capemetro

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI0 个研究点开始时间: 2008年7月8日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Histologic proof of HCC or respect of Barcelona criteria
  • No possibility of curative treatments (surgery, RF, TACE or PEI)
  • Life expectancy > 3 months
  • Child-Pugh stage A or B
  • Total bilirubine < 3 mg/dl
  • Adequate bone marrow function
  • Adequate renal and cardiac function
  • Written informed consent
  • Child-Pugh A o B Bilirubina totale < 3 mg/dl
  • Adeguata riserva midollare
  • Adeguata funzionalita' renale e cardiaca
  • Consenso informato scritto
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Severe cardiac or renal disease
  • Women of child-bearing potential that refuse adequate contraceptive measures, no
  • pregnancy or breast feeding
  • Child-Pugh stage C
  • History of hypersensitivity to 5-FU
  • Administration of any sperimental chemotherapeutic agents within the last two months
  • Any clinical conditions potentially hampering compliance with the study protocol
  • Any psychological, familial, social or geographical conditions potentially hampering
  • compliance with the study protocol

研究者

发起方
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

相似试验